Respiratory Antiviral Treatment Market 2027 By Disease Type, Drug Class and Geography | The Insight Partners

Respiratory Antiviral Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Disease Type (URTI, Influenza, Bronchiolitis, Pneumonia, Measles, Others); Drug Class (Nucleoside Analogues, Neuraminidase Inhibitors, Ion Channel Blockers, Fusion Protein Inhibitors) and Geography

Report Code: TIPRE00015810 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Respiratory antiviral drugs are used in the treatment of an infectious disease caused by a virus. Respiratory antiviral drugs are different from the antibiotics that are specifically used in the treatment of viral infections. Respiratory antiviral drugs are different from antibiotics, which fight against bacterial infections. Antiviral drugs are utilized to treat various types of respiratory conditions such as influenza, bronchiolitis, upper respiratory tract infections (URTI), pneumonia, and measles due to their effectiveness

MARKET DYNAMICS

The Respiratory Antiviral Treatment market is growing due to the rise in prevalence of viral respiratory infections, growing aged population. However, the high cost associated is expected to hamper the growth of the global Respiratory Antiviral Treatment market.

MARKET SCOPE

The "Respiratory Antiviral Treatment Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of Respiratory Antiviral Treatment market with detailed market segmentation disease type and drug class. The Respiratory Antiviral Treatment market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Respiratory Antiviral Treatment market and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The Respiratory Antiviral Treatment market is segmented on the basis of disease type and drug class. Based on disease type, the market is segmented as URTI, Influenza, Bronchiolitis, Pneumonia, Measles, & Others. Based on the drug class the market is segmented into Nucleoside Analogues, Neuraminidase Inhibitors, Ion Channel Blockers, Fusion Protein Inhibitors.

REGIONAL FRAMEWORK

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Respiratory Antiviral Treatment market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Respiratory Antiviral Treatment market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Respiratory Antiviral Treatment market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Respiratory Antiviral Treatment market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the Respiratory Antiviral Treatment market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Respiratory Antiviral Treatment market are anticipated to have lucrative growth opportunities in the future with the rising demand for Respiratory Antiviral Treatment in the global market. Below mentioned is the list of few companies engaged in the Respiratory Antiviral Treatment market.

The report also includes the profiles of key players in Respiratory Antiviral Treatment market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  F. Hoffmann-La Roche Ltd.
  •  Novartis AG
  •  Takeda Pharmaceutical Company Limited
  •  Pfizer, Inc.
  •  Teva Pharmaceutical Industries Ltd.
  •  Sun Pharmaceutical Industries Ltd.
  •  GlaxoSmithKline plc
  •  Mylan Inc.
  •  Merck & Co., Inc.
  •  AstraZeneca plc.

The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Respiratory Antiviral Treatment Market - By Disease Type
1.3.2 Respiratory Antiviral Treatment Market - By Drug Class
1.3.3 Respiratory Antiviral Treatment Market - By Region
1.3.3.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. RESPIRATORY ANTIVIRAL TREATMENT MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. RESPIRATORY ANTIVIRAL TREATMENT MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS

6. RESPIRATORY ANTIVIRAL TREATMENT MARKET - GLOBAL MARKET ANALYSIS
6.1. RESPIRATORY ANTIVIRAL TREATMENT - GLOBAL MARKET OVERVIEW
6.2. RESPIRATORY ANTIVIRAL TREATMENT - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE

7. RESPIRATORY ANTIVIRAL TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DISEASE TYPE
7.1. OVERVIEW
7.2. DISEASE TYPE MARKET FORECASTS AND ANALYSIS
7.3. URTI
7.3.1. Overview
7.3.2. URTI Market Forecast and Analysis
7.4. INFLUENZA
7.4.1. Overview
7.4.2. Influenza Market Forecast and Analysis
7.5. BRONCHIOLITIS
7.5.1. Overview
7.5.2. Bronchiolitis Market Forecast and Analysis
7.6. PNEUMONIA
7.6.1. Overview
7.6.2. Pneumonia Market Forecast and Analysis
7.7. MEASLES
7.7.1. Overview
7.7.2. Measles Market Forecast and Analysis
7.8. OTHERS
7.8.1. Overview
7.8.2. Others Market Forecast and Analysis
8. RESPIRATORY ANTIVIRAL TREATMENT MARKET - REVENUE AND FORECASTS TO 2027 - DRUG CLASS
8.1. OVERVIEW
8.2. DRUG CLASS MARKET FORECASTS AND ANALYSIS
8.3. NUCLEOSIDE ANALOGUES
8.3.1. Overview
8.3.2. Nucleoside Analogues Market Forecast and Analysis
8.4. NEURAMINIDASE INHIBITORS
8.4.1. Overview
8.4.2. Neuraminidase Inhibitors Market Forecast and Analysis
8.5. ION CHANNEL BLOCKERS
8.5.1. Overview
8.5.2. Ion Channel Blockers Market Forecast and Analysis
8.6. FUSION PROTEIN INHIBITORS
8.6.1. Overview
8.6.2. Fusion Protein Inhibitors Market Forecast and Analysis

9. RESPIRATORY ANTIVIRAL TREATMENT MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Respiratory Antiviral Treatment Market Overview
9.1.2 North America Respiratory Antiviral Treatment Market Forecasts and Analysis
9.1.3 North America Respiratory Antiviral Treatment Market Forecasts and Analysis - By Disease Type
9.1.4 North America Respiratory Antiviral Treatment Market Forecasts and Analysis - By Drug Class
9.1.5 North America Respiratory Antiviral Treatment Market Forecasts and Analysis - By Countries
9.1.5.1 United States Respiratory Antiviral Treatment Market
9.1.5.1.1 United States Respiratory Antiviral Treatment Market by Disease Type
9.1.5.1.2 United States Respiratory Antiviral Treatment Market by Drug Class
9.1.5.2 Canada Respiratory Antiviral Treatment Market
9.1.5.2.1 Canada Respiratory Antiviral Treatment Market by Disease Type
9.1.5.2.2 Canada Respiratory Antiviral Treatment Market by Drug Class
9.1.5.3 Mexico Respiratory Antiviral Treatment Market
9.1.5.3.1 Mexico Respiratory Antiviral Treatment Market by Disease Type
9.1.5.3.2 Mexico Respiratory Antiviral Treatment Market by Drug Class
9.2. EUROPE
9.2.1 Europe Respiratory Antiviral Treatment Market Overview
9.2.2 Europe Respiratory Antiviral Treatment Market Forecasts and Analysis
9.2.3 Europe Respiratory Antiviral Treatment Market Forecasts and Analysis - By Disease Type
9.2.4 Europe Respiratory Antiviral Treatment Market Forecasts and Analysis - By Drug Class
9.2.5 Europe Respiratory Antiviral Treatment Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Respiratory Antiviral Treatment Market
9.2.5.1.1 Germany Respiratory Antiviral Treatment Market by Disease Type
9.2.5.1.2 Germany Respiratory Antiviral Treatment Market by Drug Class
9.2.5.2 France Respiratory Antiviral Treatment Market
9.2.5.2.1 France Respiratory Antiviral Treatment Market by Disease Type
9.2.5.2.2 France Respiratory Antiviral Treatment Market by Drug Class
9.2.5.3 Italy Respiratory Antiviral Treatment Market
9.2.5.3.1 Italy Respiratory Antiviral Treatment Market by Disease Type
9.2.5.3.2 Italy Respiratory Antiviral Treatment Market by Drug Class
9.2.5.4 Spain Respiratory Antiviral Treatment Market
9.2.5.4.1 Spain Respiratory Antiviral Treatment Market by Disease Type
9.2.5.4.2 Spain Respiratory Antiviral Treatment Market by Drug Class
9.2.5.5 United Kingdom Respiratory Antiviral Treatment Market
9.2.5.5.1 United Kingdom Respiratory Antiviral Treatment Market by Disease Type
9.2.5.5.2 United Kingdom Respiratory Antiviral Treatment Market by Drug Class
9.2.5.6 Rest of Europe Respiratory Antiviral Treatment Market
9.2.5.6.1 Rest of Europe Respiratory Antiviral Treatment Market by Disease Type
9.2.5.6.2 Rest of Europe Respiratory Antiviral Treatment Market by Drug Class
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Respiratory Antiviral Treatment Market Overview
9.3.2 Asia-Pacific Respiratory Antiviral Treatment Market Forecasts and Analysis
9.3.3 Asia-Pacific Respiratory Antiviral Treatment Market Forecasts and Analysis - By Disease Type
9.3.4 Asia-Pacific Respiratory Antiviral Treatment Market Forecasts and Analysis - By Drug Class
9.3.5 Asia-Pacific Respiratory Antiviral Treatment Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Respiratory Antiviral Treatment Market
9.3.5.1.1 Australia Respiratory Antiviral Treatment Market by Disease Type
9.3.5.1.2 Australia Respiratory Antiviral Treatment Market by Drug Class
9.3.5.2 China Respiratory Antiviral Treatment Market
9.3.5.2.1 China Respiratory Antiviral Treatment Market by Disease Type
9.3.5.2.2 China Respiratory Antiviral Treatment Market by Drug Class
9.3.5.3 India Respiratory Antiviral Treatment Market
9.3.5.3.1 India Respiratory Antiviral Treatment Market by Disease Type
9.3.5.3.2 India Respiratory Antiviral Treatment Market by Drug Class
9.3.5.4 Japan Respiratory Antiviral Treatment Market
9.3.5.4.1 Japan Respiratory Antiviral Treatment Market by Disease Type
9.3.5.4.2 Japan Respiratory Antiviral Treatment Market by Drug Class
9.3.5.5 South Korea Respiratory Antiviral Treatment Market
9.3.5.5.1 South Korea Respiratory Antiviral Treatment Market by Disease Type
9.3.5.5.2 South Korea Respiratory Antiviral Treatment Market by Drug Class
9.3.5.6 Rest of Asia-Pacific Respiratory Antiviral Treatment Market
9.3.5.6.1 Rest of Asia-Pacific Respiratory Antiviral Treatment Market by Disease Type
9.3.5.6.2 Rest of Asia-Pacific Respiratory Antiviral Treatment Market by Drug Class
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Respiratory Antiviral Treatment Market Overview
9.4.2 Middle East and Africa Respiratory Antiviral Treatment Market Forecasts and Analysis
9.4.3 Middle East and Africa Respiratory Antiviral Treatment Market Forecasts and Analysis - By Disease Type
9.4.4 Middle East and Africa Respiratory Antiviral Treatment Market Forecasts and Analysis - By Drug Class
9.4.5 Middle East and Africa Respiratory Antiviral Treatment Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Respiratory Antiviral Treatment Market
9.4.5.1.1 South Africa Respiratory Antiviral Treatment Market by Disease Type
9.4.5.1.2 South Africa Respiratory Antiviral Treatment Market by Drug Class
9.4.5.2 Saudi Arabia Respiratory Antiviral Treatment Market
9.4.5.2.1 Saudi Arabia Respiratory Antiviral Treatment Market by Disease Type
9.4.5.2.2 Saudi Arabia Respiratory Antiviral Treatment Market by Drug Class
9.4.5.3 Rest of Middle East and Africa Respiratory Antiviral Treatment Market
9.4.5.3.1 Rest of Middle East and Africa Respiratory Antiviral Treatment Market by Disease Type
9.4.5.3.2 Rest of Middle East and Africa Respiratory Antiviral Treatment Market by Drug Class
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Respiratory Antiviral Treatment Market Overview
9.5.2 South and Central America Respiratory Antiviral Treatment Market Forecasts and Analysis
9.5.3 South and Central America Respiratory Antiviral Treatment Market Forecasts and Analysis - By Disease Type
9.5.4 South and Central America Respiratory Antiviral Treatment Market Forecasts and Analysis - By Drug Class
9.5.5 South and Central America Respiratory Antiviral Treatment Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Respiratory Antiviral Treatment Market
9.5.5.1.1 Brazil Respiratory Antiviral Treatment Market by Disease Type
9.5.5.1.2 Brazil Respiratory Antiviral Treatment Market by Drug Class
9.5.5.2 Argentina Respiratory Antiviral Treatment Market
9.5.5.2.1 Argentina Respiratory Antiviral Treatment Market by Disease Type
9.5.5.2.2 Argentina Respiratory Antiviral Treatment Market by Drug Class
9.5.5.3 Rest of South and Central America Respiratory Antiviral Treatment Market
9.5.5.3.1 Rest of South and Central America Respiratory Antiviral Treatment Market by Disease Type
9.5.5.3.2 Rest of South and Central America Respiratory Antiviral Treatment Market by Drug Class

10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

11. RESPIRATORY ANTIVIRAL TREATMENT MARKET, KEY COMPANY PROFILES
11.1. F. HOFFMANN-LA ROCHE LTD.
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. NOVARTIS AG
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. TAKEDA PHARMACEUTICAL COMPANY LIMITED
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. PFIZER, INC.
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. TEVA PHARMACEUTICAL INDUSTRIES LTD.
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. SUN PHARMACEUTICAL INDUSTRIES LTD.
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. GLAXOSMITHKLINE PLC
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. MYLAN INC.
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. MERCK AND CO., INC.
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. ASTRAZENECA PLC.
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments

12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
The List of Companies

1. F. Hoffmann-La Roche Ltd.
2. Novartis AG
3. Takeda Pharmaceutical Company Limited
4. Pfizer, Inc.
5. Teva Pharmaceutical Industries Ltd.
6. Sun Pharmaceutical Industries Ltd.
7. GlaxoSmithKline plc
8. Mylan Inc.
9. Merck and Co., Inc.
10. AstraZeneca plc.
TIPRE00015810
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking